# Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

> **NCT07185503** · — · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 60 (estimated)

## Conditions studied

- Mucormycosis in Hematologic Malignancies

## Interventions

- **DRUG:** liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole

## Key facts

- **NCT ID:** NCT07185503
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2026-06
- **Final completion:** 2027-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185503, "Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07185503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*